メインコンテンツに移動
  • 認定パートナー
  • ELGAについて
    • ELGAについて
    • 採用情報
    • イベント
  • サポート
    • ラボのプランニング
    • 製品を登録
    • Register Your Product (USA & Canada Only)
  • お問い合わせ
  • U.S.A.
  • U.K.
  • Deutschland
  • España
  • France
  • Italia
  • Brasil
  • 中国
ホーム ELGA LabWater
  • 製品
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • ELGA全製品ライン
  • 用途
    • ガスクロマトグラフィー
    • ラボ用水の一般要件
    • 免疫組織染色
    • 分光測光法
    • 原子分光学
    • 微生物学的分析
    • 液体クロマトグラフィー
    • 細胞培養
    • 臨床生化学
    • 質量分析
    • 遺伝学
    • 電気化学
  • 純水製造技術
    • PureSure
    • ろ過
    • イオン交換
    • 活性炭
    • 紫外線
    • 逆浸透(RO)
    • 電気脱イオン処理(EDI)
  • 水中の不純物
    • 微生物&細菌
    • 有機化合物
    • 溶存ガス
    • 無機化合物
    • 粒子状物質
  • Knowledge
    • ブログ
    • ケーススタディ
    • 超純水
    • ガイド&ホワイトペーパー
  • 製品
    • PURELAB
    • CENTRA
    • MEDICA
      • Hubgrade
      • MEDICA BIOX
    • BIOPURE
    • ELGA全製品ライン
      • PURELAB® Classic
  • 用途
    • ガスクロマトグラフィー
    • ラボ用水の一般要件
    • 免疫組織染色
    • 分光測光法
    • 原子分光学
    • 微生物学的分析
    • 液体クロマトグラフィー
      • Hochleistungsflüssigkeitschromatographie (HPLC)
    • 細胞培養
    • 臨床生化学
    • 質量分析
    • 遺伝学
    • 電気化学
  • 純水製造技術
    • PureSure
    • ろ過
    • イオン交換
    • 活性炭
    • 紫外線
    • 逆浸透(RO)
    • 電気脱イオン処理(EDI)
  • 水中の不純物
    • 微生物&細菌
    • 有機化合物
    • 溶存ガス
    • 無機化合物
    • 粒子状物質
  • Knowledge
    • ブログ
      • Analytical Chemistry
      • Clinical & Pharma
      • Cool Science
      • Environment and sustainability
      • Life in the lab
      • Purelab product design
      • Science of the future
      • Water Purity
      • Water in the lab
    • ケーススタディ
      • 南アジアのAbbott Diagnostics、ELGA MEDICAシステムを選択
      • Beam Me Up, Scotty: PURELAB® Option Q Delivers Essential Ultra Pure Water
      • Argenta chooses DKSH New Zealand to deliver Ultrapure water in Animal Pharma
      • Clean Water for a Clean Future
      • LS Scientific & ELGA deliver UltraPure water to the NAFDAC Laboratory
      • Lifebrain Group chooses ELGA as water partner for new modern 24/7 PCR-COVID-19 laboratory in Vienna, Austria.
      • Critital Tests Benefit from PURELAB® Option Reliable Pure Water
      • DASA:ブラジル最大の医療診断企業
      • 免疫血清学ラボの稼働時間最大化を支援するELGA
      • Fondazione Telethon Continues to Choose ELGA Labwater as a Trusted Partner
      • ジェネリック医薬品開発における超純水(I型水+)の重要性
      • Siemens ADVIA分析装置用に市立総合病院がMEDICA®Proを導入
      • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
      • PURELAB® Option R Guarantees Pure Water for Leading Microfluidics Technology
      • PURELAB® Pulse Delivers Reliable Water Quality and Quantity for a Wide Range of Applications
      • PURELAB® flex:現代的な研究手法における理想的なトレーニングシステム
      • Powering Cutting-Edge Gene Research
      • Sichere Reinstwasserversorgung für präzise Produkttests
      • Zentrale Reinstwasser-Aufbereitung für Analyser
      • ELGA LabWater and Beckman Coulter Join Forces
      • Applied New Technologies Department Improves ICP, IC & HPLC Sample Turnaround Times with PURELAB®
      • 超純水により南極の謎を解明
      • Advancing Genetic Technologies
      • Cross Infection Control: Pure and Simple
      • Researching effective new ways to prevent cardiovascular disease at the University of Columbia
    • 超純水
    • ガイド&ホワイトペーパー
      • HPLC用水の純度
      • 製薬におけるHPLC
      • 臨床でのリスクの低減
      • サステナビリティ
  • U.S.A.
  • U.K.
  • Deutschland
  • España
  • France
  • Italia
  • Brasil
  • 中国
  • プライバシーポリシー
  • 利用規約
  • 世界的な法令順守
  • 特許
  • サイト管理者情報
  • ホーム
  • Could Faecal Testing Help Personalise Cancer Treatment?
Analytical Chemistry
Water Purity

Could Faecal Testing Help Personalise Cancer Treatment?

22 6月 2020
- by Dr Alison Halliday

Scientific Testing

A new study suggests that measuring short-chain fatty acids in the gut may offer a way to predict which cancer patients will benefit from immunotherapy.


Cancer therapies that target elements of the immune system – immunotherapies – are showing remarkable results for many patients. So-called ‘immune checkpoint inhibitors’ work by interfering with the mechanism that cancer cells use to evade destruction by the body’s immune system. Examples include nivolumab and pembrolizumab, which target a molecule on the surface of cells called PD–1.

Treating patients with immune checkpoint inhibitors can shrink tumours and improve survival rates, even for whom other therapies have failed. However, the response to these drugs varies widely from person to person – particularly for those with solid tumours.

If clinicians could predict who will benefit from cancer immunotherapies in advance, this would help spare many patients from the risk of unnecessary side effects. Defining the factors that can influence this variability in response will also improve our understanding of how these treatments work, identifying new opportunities for widening their effectiveness in the future.

The Gut Microbiome is a Suspect

Several studies have suggested that the population of microorganisms in our gut may influence the success of cancer immunotherapies. But the mechanisms behind this potential association remain unclear. One suspect are the short-chain fatty acids, which are the major end–products of gut microbiome–mediated metabolism. These molecules are thought to have wide-ranging effects on the whole body – including in modulating the immune response. 

In a new study, published in JAMA Network Open, scientists set out to explore whether short-chain fatty acids are associated with the clinical outcomes of patients with solid tumours treated with nivolumab or pembrolizumab.1

Evaluating Short-Chain Fatty Acid Concentrations

The researchers recruited 52 patients with solid tumours before they started treatment with nivolumab or pembrolizumab. They collected faecal and plasma samples and measured the concentrations of various short-chain fatty acids using ultra–high–performance liquid chromatography coupled with tandem mass spectrometry.

For these experiments, they used ultrapure water from an ELGA PURELAB® flex 5 water purification system, minimising the risk of introducing contaminants that may affect their results.

The scientists carried out scans to measure the size of the patients’ tumours at regular intervals over the study. They then carried out statistical analyses to evaluate if the levels of short-chain fatty acids were related to their response to treatment. They found that high concentrations of acetic acid, propionic acid, butyric acid and valeric acid in faecal samples – and isovaleric acid in plasma – were associated with patients living longer without their disease getting any worse. 

A Non–Invasive Test

This is the first study to identify a link between short-chain fatty acids and the effectiveness of PD–1 treatment for solid cancers. 

If these results are confirmed in larger studies, testing faecal samples from patients with solid tumours could offer a relatively simple way to predict who may benefit from nivolumab or pembrolizumab– paving the way to a more personalised approach to cancer immunotherapy in the future.

Why Choose ELGA LabWater?

ELGA’s expert engineers, chemists and scientists are at the forefront of technological innovation. We continue to introduce game-changing features to the laboratory water market.
 

Reference:

  1. Nomura M, et al. Association of Short–Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment with Nivolumab or Pembrolizumab in Patients with Solid Cancer Tumors. JAMA Network Open 2020;3(4):e202895


Dr Alison Halliday

After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

risk whitepaper

When lives are at stake, there is no margin for error. Your clinical analyser must receive a constant and reliable supply of CLRW. 

Find out how to protect your test results

                   Click Here

 

  • Enquiry
  • 見積もりを取得
  • デモを予約する
  • 承認されたパートナーを見つける

Enquiry

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

見積もりを取得

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

デモを予約する

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater US Headquarters

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
電話: +44 (0) 203 567 7300
ファックス:+44 (0) 203 567 7205

ELGA LabWater本社

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
電話: +44 (0) 203 567 7300
ファックス:+44 (0) 203 567 7205

ケーススタディ

  • Abbott Diagnostics(アボットダイアグノスティクス)
  • DASA Medical Diagnostics(DASA医療診断)
  • NeoDIN Medical Institute(NeoDIN医療機関)
  • UHNS(University Hospital of North Staffordshire NHS Trust/北スタンフォードシャア大学病院)
  • Olsberg Vocational College(オルスバーグ専門学校)

リソース

  • 超純水について
  • ガイド&ホワイトペーパー
  • 純水製造技術
  • 用途
  • 水中の不純物

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • 言語
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • 他のVeoliaサイト
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies

©VWS(UK)Ltd.はELGA LabWaterとして取引されています。2022-全著作権所有。
ELGAはVeoliaのグローバルなラボ用水のブランド名です。

  • プライバシーポリシー
  • 利用規約
  • 世界的な法令順守
  • 特許
  • サイト管理者情報
Elga Veolia
TOP

© 2017 ELGA Veolia